Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 214.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,945 shares of the company's stock after purchasing an additional 30,638 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.08% of Harmony Biosciences worth $1,356,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in HRMY. Federated Hermes Inc. raised its stake in shares of Harmony Biosciences by 2,132.8% during the fourth quarter. Federated Hermes Inc. now owns 525,337 shares of the company's stock valued at $16,968,000 after acquiring an additional 501,809 shares during the last quarter. LSV Asset Management raised its stake in shares of Harmony Biosciences by 346.5% during the first quarter. LSV Asset Management now owns 335,146 shares of the company's stock valued at $11,254,000 after acquiring an additional 260,093 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Harmony Biosciences by 9.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 319,167 shares of the company's stock valued at $10,309,000 after acquiring an additional 28,256 shares during the last quarter. Capital Management Corp VA bought a new position in shares of Harmony Biosciences during the first quarter valued at about $7,018,000. Finally, Janus Henderson Group PLC raised its stake in shares of Harmony Biosciences by 1,011.7% during the first quarter. Janus Henderson Group PLC now owns 185,083 shares of the company's stock valued at $6,214,000 after acquiring an additional 168,434 shares during the last quarter. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Stock Down 1.8 %

HRMY traded down $0.64 during midday trading on Tuesday, reaching $35.80. The company's stock had a trading volume of 193,070 shares, compared to its average volume of 383,514. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of 15.50, a PEG ratio of 0.81 and a beta of 0.72. The company has a current ratio of 3.11, a quick ratio of 3.07 and a debt-to-equity ratio of 0.34. Harmony Biosciences Holdings, Inc. has a 1 year low of $18.61 and a 1 year high of $39.26. The stock's 50-day moving average is $32.27 and its 200-day moving average is $31.53.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.24. The business had revenue of $172.80 million for the quarter, compared to analysts' expectations of $172.53 million. Harmony Biosciences had a net margin of 22.30% and a return on equity of 28.26%. The business's revenue was up 28.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.56 earnings per share. As a group, research analysts expect that Harmony Biosciences Holdings, Inc. will post 1.79 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Citigroup assumed coverage on shares of Harmony Biosciences in a research note on Friday, June 21st. They set a "buy" rating and a $48.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and set a $52.00 price target on shares of Harmony Biosciences in a research report on Tuesday, August 6th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $41.67.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.